Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Mechanism of resistance to ABL tyrosine kinase inhibitor STI-571 explored

Aug. 22, 2000

Dendreon describes therapeutic cancer vaccine technology

Aug. 22, 2000

Antineoplastic agents under development at Merck & Co.

Aug. 21, 2000

Copernicus Therapeutics awarded SBIR grant to develop episomal vectors for breast cancer therapy

Aug. 21, 2000

New series under development at Pharmacia for treatment of cancer

Aug. 18, 2000

Teverelix shows promise in first-dose-in-humans study

Aug. 18, 2000

NIH licensing opportunity: system for functional identification of p53 mutations

Aug. 17, 2000

Licensing opportunity from NIH: gene amplification in cancer

Aug. 17, 2000

NIH licensing opportunity: methods to inhibit cell motility

Aug. 17, 2000

Zarix updates progress on Thymitaq

Aug. 16, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...